Medication adherence and formulation challenges — branching viva

Opening (warm-up)

Examiner: "You are the general paediatric registrar in the transplant clinic. A six-year-old renal transplant recipient has had erratic tacrolimus levels for three months despite a correct weight-based dose. I've just asked the mother how he takes it, and she tells me he spits out the bitter liquid and the half-tablets crumble. Reframe this for me — is this a pharmacology problem?" [2]

Model answer: No — this is a formulation-and-adherence problem wearing a pharmacology disguise. The dose is correct but the child cannot take the formulation he has been given, so the level bounces. Before I touch the dose I would treat the erratic level as adherence-until-proven-otherwise, ask openly how he actually takes the medicine, and fix the formulation. Adherence is a property of the prescribing, not of the child. [1] [2]

Branch 1 — probe the definitions

Examiner: "Define adherence for me, and tell me why we don't say compliance any more." [2]

Model answer: Medication adherence is the extent to which a person's medicine-taking behaviour corresponds to the agreed recommendations — it is shared, negotiated and behavioural. Compliance is the older term that implied the patient obeys the prescriber, so it framed the child or family as the problem; we now use adherence deliberately. Adherence has three dimensions — initiation (taking the first dose), implementation (taking it as prescribed day to day), and discontinuation or non-persistence (stopping). This child is an implementation problem. [2]

Examiner (corner): "And persistence?" [2]

Model answer: Persistence is the length of time a patient continues to take the medicine before stopping. It's a separate dimension from day-to-day implementation — a child can be perfectly adherent for three months and then stop entirely at adolescence. [12]

Branch 2 — why is this so common in children?

Examiner: "Why is the formulation half of adherence in a child?" [1] [3]

Model answer: Four drivers converge on a single node: the child cannot or will not take the medicine as prescribed. First, taste and palatability — children are biologically more bitter-sensitive than adults, an evolutionary poison protection, and most active ingredients are intensely bitter; a liquid an adult tolerates may be genuinely untakeable for a child (Mennella's work, 2008 and 2013). Second, swallowing readiness — safe swallowing of a standard tablet is a developmental skill acquired around five to six years, so a tablet for a young child is a formulation failure. Third, the regimen — adherence falls as dose frequency rises. Fourth, the formulation gap — Nunn and Richey's 2005 paper set out the structural problem: many drugs have no age-appropriate liquid, no palatable form, no strength-correct dose, so they are crushed, split, diluted or forced. That gap is why adherence in children is so often a prescribing problem. [1] [3]

Examiner: "Give me the prevalence headline." [2]

Model answer: Non-adherence to long-term medicines in children and adolescents is common — frequently around half or more of patients — and Dean's 2010 Archives of Disease in Childhood systematic review is the canonical reference. The pattern reproduces across chronic diseases — transplant, epilepsy, asthma, sickle cell, HIV, mental illness — which is exactly why the intervention is generic. Adolescence is the peak. [2] [12]

Branch 3 — the stepwise pathway (the core)

Examiner: "Walk me through what you actually do at this clinic visit." [2]

Model answer — six steps, in order: [2]

1. Assess adherence openly and without blame. I have already asked the mother how he takes it; I would also triangulate with the tacrolimus level and the refill record. [2]
2. Identify the barrier. Here it is primarily a formulation barrier — a bitter liquid and crumbling split tablets — possibly layered on a regimen and family barrier. [1]
3. Match the formulation to the child. With the pharmacist I would look for a taste-masked tacrolimus preparation, a dispersible form, or a mini-tablet at a weight-based strength; mini-tablets are swallowable by many children from about two years (Münch 2023). [9]
4. Simplify the regimen. Tacrolimus is twice-daily by nature, but I would align doses with daily routines (breakfast, bedtime) and provide dosing aids (oral syringes, a pill box). [2]
5. Counsel the child and family. Explain the rationale, teach technique, offer taste-masking (chilling the liquid, following with a preferred drink), and — because he is six — include him in the conversation. [3]
6. Review and reinforce. Re-assess the level and adherence at every visit; adjust the formulation as he grows. [2]

Examiner (corner): "What makes this high-risk, and what changes?" [2]

Model answer: Tacrolimus is a narrow-therapeutic-index transplant immunosuppressant, so this is high-risk by definition. For high-risk medicines I involve the specialist pharmacist at every visit, monitor the objective level routinely, plan explicit transitions (ward to home, and eventually paediatric to adult), and offer behavioural support early — I do not wait for a rejection crisis to escalate. [2]

Branch 4 — excipient safety and the neonate

Examiner: "You mentioned the formulation gap in neonates. What's different about a neonate?" [6]

Model answer: In a neonate, excipient safety is the first question, not an afterthought. Neonates handle excipients differently because of immature hepatic metabolism and renal clearance, so excipients tolerated in older children can cause real harm. The classical offenders are benzyl alcohol (gasping syndrome), propylene glycol (hyperosmolality, neurological toxicity), ethanol, and high sorbitol (osmotic diarrhoea). Allegaert's 2013 work on tailored neonatal formulations set this out, and the STEP — Safety and Toxicity of Excipients for Paediatrics — database (Salunke 2013) is the named reference I would check before prescribing any liquid in a neonate. [5] [6]

Examiner (corner): "So you wouldn't just crush a tablet for a neonate?" [1]

Model answer: Not without checking. Crushing or opening a capsule changes bioavailability, stability, and feed interactions — phenytoin and enteral feeds is the classic trap, and enteric-coated or modified-release drugs must not be crushed. I would confirm crushability and feed interactions with the pharmacist before modifying any formulation for a tube or a young child. [1]

Branch 5 — the regional regulatory picture

Examiner: "Has regulation fixed the formulation gap?" [1]

Model answer: Partially. The EU Paediatric Regulation (2007) and its Paediatric Investigation Plans require age-appropriate formulations as a condition of authorisation. In the US, BPCA (paediatric exclusivity) and PREA (mandatory paediatric assessment), made permanent under FDASIA, drive paediatric formulation development. The chewable-mebendazole and mini-tablet evidence I cited is partly the dividend of those frameworks. But the gap at the bedside has not closed as fast as the regulatory data have accumulated — neonates, neglected tropical diseases, and low-resource settings are still under-served. The honest answer is that the frameworks are necessary but not sufficient, and bedside formulation choice still does the heavy lifting. [1] [7]

Closing probe

Examiner: "Give me one sentence a parent would understand." [2]

Model answer: "Your son's medicine is right, but the form we're giving it in doesn't work for him — so together we'll find a version he can actually take, we'll fit it into your day, and we'll keep checking it's working at every visit." [2]